In most cases, FGFRL1 exhibits to promote the development and progression of tumors including bladder cancer, esophageal cancer, larynx carcinoma, lung cancer, ovarian cancer, and prostate cancer. This evidence concerns the gene FGFRL1 and lung carcinoma.